Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines

Kirsten S. Vannice, Annelies Wilder-Smith, Alan Barrett, Kalinka Carrijo, Marco Cavaleri, Aravinda de Silva, Anna P. Durbin, Tim Endy, Eva Harris, Bruce L. Innis, Leah C. Katzelnick, Peter G. Smith, Wellington Sun, Stephen J. Thomas, Joachim Hombach

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust characterization. In 2012, WHO published guidelines on the quality, safety and efficacy of live attenuated dengue tetravalent vaccines. Subsequently, efficacy and longer-term follow-up data have become available from two Phase 3 trials of a dengue vaccine, conducted in parallel, and the vaccine was licensed in December 2015. The findings and interpretation of the results from these trials released both before and after licensure have highlighted key complexities for tetravalent dengue vaccines, including concerns vaccination could increase the incidence of dengue disease in certain subpopulations. This report summarizes clinical and regulatory points for consideration that may guide vaccine developers on some aspects of trial design and facilitate regulatory review to enable broader public health recommendations for second-generation dengue vaccines.

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Dengue Vaccines
Attenuated Vaccines
dengue
vaccines
Vaccines
Licensure
Public Health
Dengue
Health Services Needs and Demand
public health
risk-benefit analysis
Vaccination
Guidelines
Safety
program planning
Incidence
vaccination
incidence

Keywords

  • Dengue
  • Dengue vaccine
  • Enhancement
  • Vaccine clinical trials
  • Vaccine regulation

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. / Vannice, Kirsten S.; Wilder-Smith, Annelies; Barrett, Alan; Carrijo, Kalinka; Cavaleri, Marco; de Silva, Aravinda; Durbin, Anna P.; Endy, Tim; Harris, Eva; Innis, Bruce L.; Katzelnick, Leah C.; Smith, Peter G.; Sun, Wellington; Thomas, Stephen J.; Hombach, Joachim.

In: Vaccine, 01.01.2018.

Research output: Contribution to journalArticle

Vannice, KS, Wilder-Smith, A, Barrett, A, Carrijo, K, Cavaleri, M, de Silva, A, Durbin, AP, Endy, T, Harris, E, Innis, BL, Katzelnick, LC, Smith, PG, Sun, W, Thomas, SJ & Hombach, J 2018, 'Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines' Vaccine. https://doi.org/10.1016/j.vaccine.2018.02.062
Vannice, Kirsten S. ; Wilder-Smith, Annelies ; Barrett, Alan ; Carrijo, Kalinka ; Cavaleri, Marco ; de Silva, Aravinda ; Durbin, Anna P. ; Endy, Tim ; Harris, Eva ; Innis, Bruce L. ; Katzelnick, Leah C. ; Smith, Peter G. ; Sun, Wellington ; Thomas, Stephen J. ; Hombach, Joachim. / Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. In: Vaccine. 2018.
@article{94da6c272e3c43ed8f62fb4326e329ba,
title = "Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines",
abstract = "Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust characterization. In 2012, WHO published guidelines on the quality, safety and efficacy of live attenuated dengue tetravalent vaccines. Subsequently, efficacy and longer-term follow-up data have become available from two Phase 3 trials of a dengue vaccine, conducted in parallel, and the vaccine was licensed in December 2015. The findings and interpretation of the results from these trials released both before and after licensure have highlighted key complexities for tetravalent dengue vaccines, including concerns vaccination could increase the incidence of dengue disease in certain subpopulations. This report summarizes clinical and regulatory points for consideration that may guide vaccine developers on some aspects of trial design and facilitate regulatory review to enable broader public health recommendations for second-generation dengue vaccines.",
keywords = "Dengue, Dengue vaccine, Enhancement, Vaccine clinical trials, Vaccine regulation",
author = "Vannice, {Kirsten S.} and Annelies Wilder-Smith and Alan Barrett and Kalinka Carrijo and Marco Cavaleri and {de Silva}, Aravinda and Durbin, {Anna P.} and Tim Endy and Eva Harris and Innis, {Bruce L.} and Katzelnick, {Leah C.} and Smith, {Peter G.} and Wellington Sun and Thomas, {Stephen J.} and Joachim Hombach",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2018.02.062",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines

AU - Vannice, Kirsten S.

AU - Wilder-Smith, Annelies

AU - Barrett, Alan

AU - Carrijo, Kalinka

AU - Cavaleri, Marco

AU - de Silva, Aravinda

AU - Durbin, Anna P.

AU - Endy, Tim

AU - Harris, Eva

AU - Innis, Bruce L.

AU - Katzelnick, Leah C.

AU - Smith, Peter G.

AU - Sun, Wellington

AU - Thomas, Stephen J.

AU - Hombach, Joachim

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust characterization. In 2012, WHO published guidelines on the quality, safety and efficacy of live attenuated dengue tetravalent vaccines. Subsequently, efficacy and longer-term follow-up data have become available from two Phase 3 trials of a dengue vaccine, conducted in parallel, and the vaccine was licensed in December 2015. The findings and interpretation of the results from these trials released both before and after licensure have highlighted key complexities for tetravalent dengue vaccines, including concerns vaccination could increase the incidence of dengue disease in certain subpopulations. This report summarizes clinical and regulatory points for consideration that may guide vaccine developers on some aspects of trial design and facilitate regulatory review to enable broader public health recommendations for second-generation dengue vaccines.

AB - Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust characterization. In 2012, WHO published guidelines on the quality, safety and efficacy of live attenuated dengue tetravalent vaccines. Subsequently, efficacy and longer-term follow-up data have become available from two Phase 3 trials of a dengue vaccine, conducted in parallel, and the vaccine was licensed in December 2015. The findings and interpretation of the results from these trials released both before and after licensure have highlighted key complexities for tetravalent dengue vaccines, including concerns vaccination could increase the incidence of dengue disease in certain subpopulations. This report summarizes clinical and regulatory points for consideration that may guide vaccine developers on some aspects of trial design and facilitate regulatory review to enable broader public health recommendations for second-generation dengue vaccines.

KW - Dengue

KW - Dengue vaccine

KW - Enhancement

KW - Vaccine clinical trials

KW - Vaccine regulation

UR - http://www.scopus.com/inward/record.url?scp=85042870520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042870520&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.02.062

DO - 10.1016/j.vaccine.2018.02.062

M3 - Article

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -